Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure.
Gregor PoglajenGregor ZemljičSabina FrljakAndraz CerarVesna AndročecMatjaž SeverPeter ČernelčPublished in: Stem cells international (2018)
The trials of stem cell therapy in DCMP patients have shown some promising results, thus making DCMP apparently more inviting target for stem cell therapy than chronic ischemic heart failure, where studies to date failed to demonstrate a consistent effect of stem cells on myocardial performance. Future stem cell strategies should aim for more personalized therapeutic approach by establishing the optimal stem cell type or their combination, dose, and delivery method for an individual patient adjusted for patient's age and stage of the disease.
Keyphrases
- cell therapy
- stem cells
- heart failure
- left ventricular
- end stage renal disease
- case report
- cardiac resynchronization therapy
- ejection fraction
- mesenchymal stem cells
- newly diagnosed
- peritoneal dialysis
- atrial fibrillation
- prognostic factors
- acute heart failure
- brain injury
- patient reported outcomes
- ischemia reperfusion injury
- oxidative stress
- patient reported
- bone marrow
- replacement therapy